Novavax, Inc. (FRA:NVV1)
Germany · Delayed Price · Currency is EUR | Market Cap | 1.27B -4.0% |
| Revenue (ttm) | 907.40M +20.3% |
| Net Income | 291.27M |
| EPS | 1.76 |
| Shares Out | n/a |
| PE Ratio | 4.36 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | 2,926 |
| Open | 7.75 |
| Previous Close | 7.82 |
| Day's Range | 7.75 - 7.75 |
| 52-Week Range | 4.56 - 9.00 |
| Beta | n/a |
| RSI | 58.80 |
| Earnings Date | Feb 26, 2026 |
About Novavax
Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adoles... [Read more]
Financial Performance
In 2024, Novavax's revenue was $682.16 million, a decrease of -30.65% compared to the previous year's $983.71 million. Losses were -$187.50 million, -65.60% less than in 2023.
Financial numbers in USD Financial StatementsNews
Novavax to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
GAITHERSBURG, Md., Feb. 19, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced it will report its fourth quarter and full year 2025 financial results and operational highlights at 8:30 ...
Pfizer Likely To Report Lower Q4 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Pfizer Inc. (NYSE: PFE) will release earnings results for its fourth quarter, before the opening bell on Tuesday, Feb. 3. Analysts expect the New York-based company to report quarterly earnings at 57...
Moderna Vs. Novavax: 2 Pandemic Vaccine Pioneers - Which Offers Better Value Today?
Moderna, Inc. and Novavax, Inc. have transitioned from pandemic-era highs to focusing on cost reduction, pipeline development, and a path to breakeven by 2028. NVAX leverages partnerships with Sanofi ...
This Beaten-Down Biotech Is Showing Signs of Life. Is It a Buy?
Novavax signed a potentially lucrative deal with a pharmaceutical giant. However, the biotech's core business remains uncertain.
Why Is Pfizer Stock Rising Tuesday?
Pfizer Inc. (NYSE: PFE) shares are trading higher on Tuesday, as the stock benefits from a price forecast increase at Cantor Fitzgerald . The firm raised its forecast to $27 from $24, providing a cat...
Novavax Stock Is Surging Monday: What's Driving The Action?
Novavax Inc (NASDAQ: NVAX) shares are up on Monday following a recent licensing agreement with Pfizer Inc (NYSE: PFE) for its Matrix-M adjuvant, while renewed concerns around elevated respiratory il...
What's Driving the Market Sentiment Around Novavax Inc?
Novavax Inc's (NYSE: NVAX) short interest as a percent of float has risen 4.06% since its last report. According to exchange reported data, there are now 54.72 million shares sold short , which is 33...
Here's Why Pfizer Is Willing To Pay $500 Million For Novavax's Matrix-M
Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.
Novavax Shares Rise After Licensing Deal With Pfizer
Novavax shares are trading higher Tuesday after ... Full story available on Benzinga.com
Novavax (NVAX) Surges on Licensing Deal with Pfizer
Novavax (NVAX) Surges on Licensing Deal with Pfizer
Novavax rises after licensing deal with Pfizer
Novavax (NVAX) stock jumps as the company announces a licensing deal with Pfizer (PFE) for its Matrix-M adjuvant. Read more here.
Novavax Licenses Matrix-M Adjuvant To Pfizer For Upfront Payment Of $30 Mln
(RTTNews) - Novavax, Inc. (NVAX) announced Tuesday that it has entered into a license agreement with Pfizer, Inc. (PFE) for use of Novavax's Matrix-M adjuvant. Under the terms of the agreement, Pfizer...
Novavax Announces Entering into a License Agreement with Pfizer
Non-exclusive license allows for development by Pfizer to utilize Matrix-M ® for up to two disease areas with its products Provides Novavax with an upfront payment of $30 million with the potential fo...
Novavax enters license agreement with Pfizer for vaccine development
Novavax said on Tuesday it was entering into a licensing agreement with Pfizer to develop vaccine products for infectious diseases.
Notable Friday Option Activity: BLSH, HIMS, NVAX
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Bullish Ordinary Shares (Symbol: BLSH), where a total volume of 12,696 contracts h...
Novavax Inc at JPMorgan Healthcare Conference Transcript
Novavax Inc at JPMorgan Healthcare Conference Transcript
Novavax, Inc. (NVAX) Presents at 44th Annual J.P. Morgan Healthcare Conference
Novavax, Inc. (NVAX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Novavax, Inc. (NVAX) 44th Annual J.P.
Novavax (NVAX) Moves 11.9% Higher: Will This Strength Last?
Novavax (NVAX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in ...
CORRECTED: Why Is Novavax Stock Soaring?
Novavax Inc (NASDAQ:NVAX) shares are trading ... Full story available on Benzinga.com
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know
Novavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Novavax to Participate in the 44th Annual J.P. Morgan Healthcare Conference
GAITHERSBURG, Md., Jan. 7, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it will participate in the 44th Annual J.P.
Noteworthy Tuesday Option Activity: M, TEM, NVAX
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Macy's Inc (Symbol: M), where a total volume of 46,232 contracts has been traded t...
Interesting NVAX Call Options For February 2026
Investors in Novavax, Inc. (Symbol: NVAX) saw new options become available this week, for the February 2026 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NVAX...
Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know
Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.